AXL is a logical molecular target in head and neck squamous cell carcinoma

PURPOSE: Head and neck squamous cell carcinoma (HNSCC) represents the eighth most common malignancy worldwide. Standard of care treatments for HNSCC patients include surgery, radiation and chemotherapy. Additionally, the anti-epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab is o...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Cancer Res
Auteurs principaux: Brand, Toni M., Iida, Mari, Stein, Andrew P., Corrigan, Kelsey L., Braverman, Cara M., Coan, John, Pearson, Hannah E., Bahrar, Harsh, Fowler, Tyler L., Bednarz, Bryan P., Saha, Sandeep, Yang, David, Gill, Parkash S., Lingen, Mark W., Saloura, Vassiliki, Villaflor, Victoria M., Salgia, Ravi, Kimple, Randall J., Wheeler, Deric L.
Format: Artigo
Langue:Inglês
Publié: 2015
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5032632/
https://ncbi.nlm.nih.gov/pubmed/25767293
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-2648
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires